Showing results (91-100 of 618) with videos related to

Sort By:
Pageof 62
Therapeutic Advances in Neurological Disorders|March 8, 2018
Imaging in neuro-oncologyHari Nandu, Patrick Y Wen, Raymond Y Huang
Current Opinion in Neurology|December 9, 2008
Emerging antiangiogenic treatments for gliomas - efficacy and safety issuesJörg Dietrich, Andrew D Norden, Patrick Y Wen
Current Neurology and Neuroscience Reports|July 1, 2020
Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation ToxicityRifaquat Rahman, Brian M Alexander, Patrick Y Wen
Neuro-Oncology Practice|March 27, 2023
The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patientsMatthew Torre, Patrick Y Wen, J Bryan Iorgulescu
Neuro-Oncology|October 5, 2024
Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunitiesPatrick Y Wen, Matthias Preusser, Nathalie L Albert
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 9, 2026
Clinical outcomes after transition from weight-based to fixed-dose glucarpidase for high-dose methotrexate toxicity at a large academic medical centerMelissa L Bastacky, Mario Martinez, Shrina Duggal, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2010
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastomaJan Drappatz, Andrew D Norden, Eric T Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2013
Phase I study of GRN1005 in recurrent malignant gliomaJan Drappatz, Andrew Brenner, Eric T Wong, et al.
Neuro-Oncology|April 12, 2008
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSantosh Kesari, David Schiff, John W Henson, et al.
Brain and Behavior|April 1, 2014
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapyMatthew J Oborski, Charles M Laymon, Frank S Lieberman, et al.
Pageof 62